Mylan Laboratories Limited — Rosuvastatin Exporter Profile
Indian Pharmaceutical Exporter · #10 for Rosuvastatin · $13.0M export value · DGFT Verified
Mylan Laboratories Limited is the #10 Indian exporter of Rosuvastatin with $13.0M in export value and 621 verified shipments. Mylan Laboratories Limited holds a 2.8% market share in Rosuvastatin exports across 9 countries. The company exports 91 pharmaceutical products worth $634.8M across 26 therapeutic categories.
Mylan Laboratories Limited — Rosuvastatin Export Profile: Buyers & Destinations
Where Does Mylan Laboratories Limited Export Rosuvastatin?
| Country | Value | Shipments | Share |
|---|---|---|---|
| FRANCE | $5.3M | 193 | 46.1% |
| NETHERLANDS | $2.1M | 218 | 18.5% |
| ITALY | $1.6M | 67 | 13.6% |
| NEW ZEALAND | $1.3M | 46 | 11.7% |
| BELGIUM | $395.0K | 35 | 3.4% |
| TAIWAN | $389.0K | 10 | 3.4% |
| SPAIN | $284.8K | 32 | 2.5% |
| IRELAND | $90.8K | 15 | 0.8% |
| HUNGARY | $4.3K | 5 | 0.0% |
Mylan Laboratories Limited exports Rosuvastatin to 9 countries. The largest destination is FRANCE accounting for 46.1% of Mylan Laboratories Limited's Rosuvastatin shipments, followed by NETHERLANDS (18.5%) and ITALY (13.6%). These destinations reflect Mylan Laboratories Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Rosuvastatin from Mylan Laboratories Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| CSP VIATRIS SANTE AT CSP- LAB, | FRANCE | $1.1M | 51 |
| MYLAN IRELAND C/O ALLOGA RDC, | NETHERLANDS | $759.6K | 79 |
| CSP MYLAN SAS AT CSP LABO 274 | FRANCE | $703.7K | 20 |
| CSP VIATRIS SANTE AT CSP- LAB | FRANCE | $631.1K | 17 |
| CSP VIATRIS SANTE AT CSP LAB | FRANCE | $613.8K | 17 |
| VIATRIS LIMITED | NEW ZEALAND | $533.7K | 20 |
| CSP VIATRIS SANTE AT CSP-LAB | FRANCE | $443.2K | 12 |
| VIATRIS LIMITED, | NEW ZEALAND | $435.9K | 13 |
| VIATRIS ITALIA S.R.L. | ITALY | $418.5K | 21 |
| M/S. CSP MYLAN SAS AT CSP LABO 274 | FRANCE | $386.0K | 13 |
Mylan Laboratories Limited supplies Rosuvastatin to 79 buyers globally. The largest buyer is CSP VIATRIS SANTE AT CSP- LAB, (FRANCE), followed by MYLAN IRELAND C/O ALLOGA RDC, (NETHERLANDS) and CSP MYLAN SAS AT CSP LABO 274 (FRANCE). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Rosuvastatin Export Value and How Much Does Mylan Laboratories Limited Contribute?
India exported $321.1M worth of Rosuvastatin through 13,477 shipments from 427 suppliers to 143 countries, serving 1,314 buyers globally. Mylan Laboratories Limited contributes $13.0M to this total, accounting for 2.8% of India's Rosuvastatin exports. Mylan Laboratories Limited ships Rosuvastatin to 9 countries through 79 buyers.
What Is the Average Shipment Value for Mylan Laboratories Limited's Rosuvastatin Exports?
Mylan Laboratories Limited's average Rosuvastatin shipment value is $21.0K per consignment, based on 621 shipments totaling $13.0M. The largest destination is FRANCE (46.1% of Mylan Laboratories Limited's Rosuvastatin exports).
How Does Mylan Laboratories Limited Compare to Other Indian Rosuvastatin Exporters?
Mylan Laboratories Limited ranks #10 among 427 Indian Rosuvastatin exporters with a 2.8% market share. The top 3 exporters are MSN LABORATORIES PRIVATE LIMITED ($58.9M), GLENMARK PHARMACEUTICALS LIMITED ($44.3M), BIOCON PHARMA LIMITED ($32.6M). Mylan Laboratories Limited processed 621 shipments to 9 destination countries.
What Rosuvastatin Formulations Does Mylan Laboratories Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| ROSUVASTATINE MYLAN 5 MG TAB 90 BL PACKS | $279.7K | 8 |
| HARMLESS MEDICINES, ROSUVASTATINE MYLAN | $249.3K | 18 |
| HARMLESS MEDICINES, ROSUVASTATINA MYLAN | $218.7K | 7 |
| ROSUVASTATINE MYLAN 5 MG 30BL TAB PACKS | $218.2K | 6 |
| ROSUVASTATINE MYLAN 5 MG TAB 90BL PACKS | $205.7K | 5 |
| ROSUVASTATINE MYLAN 5 MG 30 BL TAB PACKS | $184.4K | 5 |
| ROSUVASTATINE MYLAN 10 MG 30 BL TAB PACK | $157.7K | 5 |
| ROSUVASTATINE MYLAN 20 MG 90 BL TAB PACK | $150.0K | 3 |
| ROSUVASTATINE MYLAN 20 MG 30 BL TAB PACK | $122.5K | 3 |
| HARMLESS MEDICINES, ROSUVASTATIN VIATRISTAB 40MG 30 BOT NZ (59026 PACKS) | $121.1K | 3 |
Mylan Laboratories Limited exports 410 distinct Rosuvastatin formulations including tablets, capsules, syrups, and combination drugs. The top formulation is ROSUVASTATINE MYLAN 5 MG TAB 90 BL PACKS with 8 shipments worth $279.7K.
How Does Mylan Laboratories Limited Compare to Nearest Rosuvastatin Exporters?
Exporters ranked immediately above and below #10 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | STRIDES PHARMA SCIENCE LIMITED | $21.0M | 420 | 3 | $50.0K |
| 8 | MEDREICH LIMITED | $16.7M | 684 | 13 | $24.5K |
| 10 | MYLAN LABORATORIES LIMITED ★ | $13.0M | 621 | 9 | $21.0K |
| 11 | HETERO LABS LIMITED | $11.7M | 239 | 10 | $48.9K |
| 9 | AUROBINDO PHARMA LIMITED | $10.7M | 213 | 6 | $50.0K |
Mylan Laboratories Limited ranks #10 among 427 Indian Rosuvastatin exporters. Average shipment value of $21.0K compared to the market average of $751.9K. The closest competitors by value are STRIDES PHARMA SCIENCE LIMITED and MEDREICH LIMITED.
Which Indian Ports Ship Rosuvastatin Exports?
| Port | Shipments | % Share |
|---|---|---|
| NHAVA SHEVA SEA (INNSA1) | 1,090 | 8.1% |
| SAHAR AIR | 921 | 6.8% |
| SAHAR AIR CARGO ACC (INBOM4) | 909 | 6.7% |
| HYDERABAD ICD (INSNF6) | 878 | 6.5% |
| DELHI AIR CARGO ACC (INDEL4) | 769 | 5.7% |
| JNPT/ NHAVA SHEVA SEA | 699 | 5.2% |
| DELHI AIR | 635 | 4.7% |
| HYDERABAD ICD | 550 | 4.1% |
What Other Cardiovascular Products Does Mylan Laboratories Limited Export?
Mylan Laboratories Limited also exports these cardiovascular products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Mylan Laboratories Limited's Rosuvastatin Exports
Mylan's export operations are influenced by a complex geopolitical landscape. The Israel-Iran tensions have led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. Major shipping lines have implemented 'Emergency Risk Surcharges' ranging from $250 to $500 per TEU, directly impacting the cost structure for Indian pharmaceutical exporters like Mylan. Additionally, diversions around the Cape of Good Hope have further elongated delivery schedules, posing challenges to time-sensitive pharmaceutical shipments.
In the United States, the imposition of tariffs on pharmaceutical imports has prompted Indian companies to reassess their market strategies. While generics have largely remained exempt, the potential for future tariff expansions necessitates vigilance. Mylan, along with other Indian exporters, is exploring market diversification to mitigate reliance on the U.S. market. The recent India-European Union Free Trade Agreement (FTA), signed in January 2026, offers a strategic avenue for expansion. The FTA eliminates tariffs on approximately 97% of EU tariff lines, including pharmaceuticals, thereby enhancing market access for Indian exporters. This agreement is expected to significantly boost India's pharmaceutical exports to Europe, providing a counterbalance to uncertainties in the U.S. market.
Mylan Laboratories Limited — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards remains paramount for Mylan. The FDA's warning letter and import alert in December 2024 concerning the Indore facility underscore the critical importance of stringent quality control measures. The cited violations, including subpar quality control and improper management of manufacturing defects, have necessitated comprehensive corrective actions. Mylan's proactive response aims to restore compliance and reinforce its commitment to quality assurance.
The evolving regulatory environment, particularly in the European Union, further emphasizes the need for adherence to Good Manufacturing Practices (GMP). The EU's Falsified Medicines Directive mandates rigorous compliance to ensure product integrity and patient safety. For Mylan, aligning with these standards is essential to maintain and expand its foothold in the European market.
About Mylan Laboratories Limited
Mylan Laboratories Limited exports 91 products worth $634.8M. Beyond Rosuvastatin, top products include Tenofovir, Pantoprazole, Valsartan, Ritonavir, Trastuzumab. View the complete Mylan Laboratories Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Rosuvastatin — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Rosuvastatin shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Mylan Laboratories Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 621 individual customs records matching Mylan Laboratories Limited exporting Rosuvastatin, covering 410 formulations to 9 countries via 79 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 143+ countries, 1,314+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Rosuvastatin Export Data from Mylan Laboratories Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Mylan Laboratories Limited's Rosuvastatin exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Mylan Laboratories Limited
Full Company Profile →
91 products · $634.8M total trade · 26 categories
Rosuvastatin Stats
Company Overview
Top Products by Mylan Laboratories Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Mylan Laboratories Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Rosuvastatin. For current shipment-level data, contact TransData Nexus.